Christopher Degnan
2019
In 2019, Christopher Degnan earned a total compensation of $2.2M as Chief Financial Officer at Galera Therapeutics.
Compensation breakdown
| Bonus | $70,000 |
|---|---|
| Non-Equity Incentive Plan | $23,252 |
| Option Awards | $2,059,347 |
| Salary | $76,487 |
| Total | $2,229,086 |
Degnan received $2.1M in option awards, accounting for 92% of the total pay in 2019.
Degnan also received $70K in bonus, $23.3K in non-equity incentive plan and $76.5K in salary.
Rankings
In 2019, Christopher Degnan's compensation ranked 5,372nd out of 13,971 executives tracked by ExecPay. In other words, Degnan earned more than 61.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,372 out of 13,971 | 62nd |
Division Manufacturing | 2,010 out of 5,701 | 65th |
Major group Chemicals And Allied Products | 713 out of 2,200 | 68th |
Industry group Drugs | 597 out of 1,886 | 68th |
Industry Pharmaceutical Preparations | 443 out of 1,398 | 68th |
Source: SEC filing on April 27, 2020.
Degnan's colleagues
We found two more compensation records of executives who worked with Christopher Degnan at Galera Therapeutics in 2019.
News
Galera Therapeutics CEO J Sorensen's 2023 pay slips 8% to $1.3M
January 24, 2025
Galera Therapeutics CEO J Sorensen's 2022 pay falls 46% to $1.4M
April 27, 2023
Galera Therapeutics CEO J Sorensen's 2021 pay slips 14% to $2.5M
April 28, 2022
Galera Therapeutics CEO J Sorensen's 2019 pay jumps 373% to $2.5M
April 27, 2020